Brokerages expect MediWound Ltd. (NASDAQ:MDWD) to post $5.30 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for MediWound’s earnings, with the highest sales estimate coming in at $5.60 million and the lowest estimate coming in at $5.00 million. MediWound posted sales of $4.44 million during the same quarter last year, which suggests a positive year-over-year growth rate of 19.4%. The company is scheduled to report its next earnings report before the market opens on Wednesday, May 5th.
On average, analysts expect that MediWound will report full-year sales of $30.40 million for the current year, with estimates ranging from $29.60 million to $31.20 million. For the next year, analysts expect that the business will report sales of $17.85 million, with estimates ranging from $16.20 million to $19.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for MediWound.
MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.05. MediWound had a negative net margin of 53.12% and a negative return on equity of 94.63%. The firm had revenue of $6.67 million for the quarter, compared to analyst estimates of $5.59 million.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Essex Investment Management Co. LLC bought a new position in MediWound during the fourth quarter worth $982,000. Wells Fargo & Company MN raised its holdings in MediWound by 7.4% during the fourth quarter. Wells Fargo & Company MN now owns 265,247 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 18,390 shares during the last quarter. Mission Wealth Management LP acquired a new position in MediWound during the fourth quarter worth $39,000. Squarepoint Ops LLC acquired a new position in MediWound during the third quarter worth $116,000. Finally, Sargent Investment Group LLC raised its holdings in MediWound by 32.1% during the fourth quarter. Sargent Investment Group LLC now owns 337,550 shares of the biopharmaceutical company’s stock worth $1,249,000 after buying an additional 82,050 shares during the last quarter. 16.02% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:MDWD traded down $0.19 during trading on Friday, reaching $4.68. The stock had a trading volume of 200 shares, compared to its average volume of 146,491. The firm’s fifty day moving average is $5.09 and its 200 day moving average is $4.56. MediWound has a 52 week low of $1.73 and a 52 week high of $6.07. The stock has a market cap of $127.47 million, a price-to-earnings ratio of -11.70 and a beta of 1.63.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Recommended Story: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.